Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Novel Therapy, Toripalimab, Developed to Treat Nasopharyngeal Carcinoma
Toripalimab, a novel therapy has been discovered for the treatment of nasopharyngeal carcinoma by Junshi Biosciences. Toripalimab, the first anti-PD-1 monoclonal antibody developed for the treatment of Nasopharyngeal carcinoma...
Plinabulin Developed to Prevent Chemotherapy-Induced Neutropenia
BeyondSpring Inc develops breakthrough therapy Plinabulin, for chemotherapy-induced neutropenia indication for patients with cancer. Plinabulin is a first-in-class differentiated immune and stem cell modulator....
Kesimpta® (ofatumumab), The First Self Administrated B-cell Therapy Developed
Novartis develops the first and only self administered B-cell therapy, Kesimpta®, for the treatment of relapsing Multiple sclerosis (MS). Kesimpta® becomes the first new B-cell therapy, which can be self-administered once in a month at home by means of Sensoready® autoinjector pen....
GSK Introduces a New Anti-BCMA (B-cell maturation antigen) Therapy, BLENREP
GlaxoSmithKline plc, introduces BLENREP a first-in-class anti-BCMA (B-cell maturation antigen) therapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior therapies including an anti-CD38 monoclonal antibody...
AXS-12 Novel Therapy Discovered for the Treatment of Narcolepsy
Axsome Therapeutics, Inc discovered AXS-12 novel therapy for the treatment of cataplexy in patients with narcolepsy. AXS-12 is an oral, highly selective and potent norepinephrine reuptake inhibitor. AXS-12, developed for cataplexy highlights its potential and provides meaningful benefit and substantial improvement for patients over currently available treatment...
Rozlytrek® (entrectinib), The First Tumour-Agnostic Therapy Discovered
Rozlytrek® (entrectinib), the first tumour-agnostic therapy discovered for the treatment of patients with NTRK fusion-positive, locally advanced or metastatic solid tumours in adult and paediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies....
AstraZeneca Introduces A Breakthrough Therapy-Tagrisso
AstraZeneca introduced Tagrisso (osimertinib), a breakthrough therapy for the adjuvant treatment of patients with early-stage (IB, II and IIIA) Epidermal Growth Factor Receptor-mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC)....
Merck Discovers Breakthrough Therapy HIF-2α Inhibitor MK-6482
Hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel breakthrough therapy discovered by Merck for the treatment of patients with von Hippel-Lindau (VHL) disease-associated Renal Cell Carcinoma (RCC)....
Pevonedistat Novel Therapy Developed for the Treatment of Patients with HR-MDS
Takeda Pharmaceutical has developed Pevonedistat, a NEDD8-activating enzyme (NAE) inhibitor,a novel treatment for Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients....
TECARTUS™ Discovered for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Kite discovered Tecartus™ (brexucabtageneautoleucel, formerly KTE-X19), a novel Chimeric Antigen Receptor (CAR) T for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (MCL)....
